REGENXBIO Inc.
RGNX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $170M | $83.3M | +105% |
| Operating income | −$161M | −$233M | +30.9% |
| Net income | −$194M | −$227M | +14.6% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $9.20M | $29.7M | −69.0% |
| Operating income | −$35.5M | −$52.4M | +32.3% |
| Net income | −$40.7M | −$61.9M | +34.2% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was REGENXBIO's revenue in FY2025?
- $170M in FY2025 (Fiscal year ended Dec 31, 2025), +105% vs $83.3M a year earlier, per its 10-K filed Mar 2026.
- Was REGENXBIO profitable in FY2025?
- No: net income was −$194M and operating income −$161M in FY2025.
- What was REGENXBIO's revenue in Q3 2026?
- $9.20M (−69.0% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.